FDA Releases Guidance on Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations

Summary

The FDA has announced the availability of a guidance document that explains when the agency will not object to waiving or altering informed consent requirements for certain minimal risk clinical investigations, and how sponsors and investigators can initiate or conduct such studies.